# Angiodynamics Inc: Form 10-Q for the period ended Nov 30, 2021

- Company: [Angiodynamics Inc](/companies/ango.md) (CIK 1275187)
- Form: 10-Q
- Filed: 2022-01-07
- Accepted by EDGAR: Jan 7, 2022, 12:26 ET
- Period: 2021-11-30
- Accession: 0001275187-22-000005
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1275187/000127518722000005/ango-20211130.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1275187/000127518722000005/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-11-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-09-01 to 2021-11-30 | $78.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2021-06-01 to 2021-11-30 | $155.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-09-01 to 2021-11-30 | $37.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2021-06-01 to 2021-11-30 | $74.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-09-01 to 2021-11-30 | $40.6m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2021-06-01 to 2021-11-30 | $80.7m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-09-01 to 2021-11-30 | $8.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2021-06-01 to 2021-11-30 | $15.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-09-01 to 2021-11-30 | −$8.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-06-01 to 2021-11-30 | −$16.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-09-01 to 2021-11-30 | $174.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2021-06-01 to 2021-11-30 | $330.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-09-01 to 2021-11-30 | −$512.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2021-06-01 to 2021-11-30 | −$2.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-09-01 to 2021-11-30 | −$8.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-06-01 to 2021-11-30 | −$15.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-09-01 to 2021-11-30 | −$0.21 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2021-06-01 to 2021-11-30 | −$0.39 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-09-01 to 2021-11-30 | −$0.21 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2021-06-01 to 2021-11-30 | −$0.39 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-09-01 to 2021-11-30 | 39,053,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2021-06-01 to 2021-11-30 | 38,893,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2021-06-01 to 2021-11-30 | −$7.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-06-01 to 2021-11-30 | $2.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-11-30 | $34.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-11-30 | $132.2m | us-gaap:AssetsCurrent |
| Total assets | at 2021-11-30 | $554.1m | us-gaap:Assets |
| Current liabilities | at 2021-11-30 | $54.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-11-30 | $121.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-11-30 | $432.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 28,555 characters.

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q. The following discussion should be read in conjunction with the Company's 2021 Annual Report on Form 10-K, and the consolidated financial statements and notes thereto included elsewhere in the Form 10-Q.

### Disclosure Regarding Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from our expectations, expressed or implied. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions (including inflation and labor shortages), general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, our ability to integrate purchased businesses and other factors including natural disasters and pandemics (such as the scope, scale and duration of the impact of COVID-19). Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the Securities and Exchange Commission (the "SEC").

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this report. AngioDynamics disclaims any obligation to update the forward-looking statements.

### Disclosure Regarding Trademarks

This report includes trademarks, tradenames and service marks that are our property or the property of other third parties. Solely for convenience, such trademarks and tradenames sometimes appear without any “™” or “®” symbol. However, failure to include such symbols is not intended to suggest, in any way, that we will not assert our rights or the rights of any applicable licensor, to these trademarks and tradenames. For a complete listing of all our trademarks, tradenames and service marks please visit www.angiodynamics.com/IP. Information on our website or connected to our website is not incorporated by reference into this Quarterly Report on Form 10-Q.

### Executive Overview

We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Many of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use.

Our business operations cross a variety of markets. Our financial performance is impacted by changing market dynamics, which have included an emergence of value-based purchasing by healthcare providers, consolidation of healthcare providers, the increased role of the consumer in health care decision-making and an aging population, among others. In addition, our growth is impacted by changes within our sector, such as the merging of competitors to gain scale and influence; changes in the regulatory environment for medical devices; and fluctuations in the global economy.

Our sales and profitability growth also depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions of our product offerings are created through internal and external product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in research and development activities and selective business development opportunities to provide growth opportunities.

We sell our products in the United States primarily through a direct sales force, and outside the U.S. through a combination of direct sales and distributor relationships. Our end users include interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses. We expect our businesses to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products and increasing our presence internationally.

The COVID-19 global pandemic has impacted our business and may continue to pose future risks with the emergence of new variants. Even with the public health actions that have been taken to reduce the spread of the virus, the market continues to experience disruptions with respect to consumer demand, hospital operating procedures and workflow, trends that may continue. The Company's ability to manufacture products, the reliability of our supply chain, labor shortages, backlog and inflation (including the cost of raw materials, direct labor and shipping) have impacted our business, trends that may continue. Accordingly, management continues to evaluate the Company’s liquidity position, communicate with and monitor the actions of our customers and suppliers, and review our near-term financial performance.

In evaluating the operating performance of our business, management focuses on revenue, gross margin, operating income, earnings per share and cash flow from operations. A summary of these key financial metrics for the three and six months ended November 30, 2021 compared to the three and six months ended November 30, 2020 are as follows:

Three months ended November 30, 2021:

- Revenue increased by 7.6% to $78.3 million.
- Med Tech growth of 36.4% and Med Device growth of 0.8%.
- Gross profit decreased 340 bps to 51.8%.
- Net loss increased by $4.1 million to $8.4 million.
- Loss per share increased by $0.10 to a loss of $0.21.

Six months ended November 30, 2021:

- Revenue increased by 8.6% to $155.3 million.
- Med Tech growth of 50.0% and Med Device growth of 0.1%.
- Gross profit decreased 110 bps to 52.0%.
- Net loss increased by $6.8 million to $15.3 million.
- Loss per share increased by $0.17 to a loss of $0.39.
- Cash used in operations increased by $13.0 million to $7.0 million.

In our Med Tech business, comprised of Auryon, the Thrombectomy portfolio and NanoKnife, Auryon and the Thrombectomy portfolio experienced improved performance during the second quarter of fiscal year 2022 as the number of procedures increased. In our Med Device business, Vascular Access, also improved in the second quarter of fiscal year 2022 compared to the prior year period. This was partially offset by our Oncology products, which continued to face pressure from reductions in procedure volumes due to challenges resulting from the COVID-19 pandemic.

### Results of Operations

For the three months ended November 30, 2021, the Company reported a net loss of $8.4 million, or a loss of $0.21 per diluted share, on net sales of $78.3 million, compared with a net loss of $4.3 million, or a loss of $0.11 per diluted share, on net sales of $72.8 million during the same quarter of the prior year. For the six months ended November 30, 2021, the Company reported a net loss of $15.3 million, or a loss of $0.39 per diluted share, on net sales of $155.3 million, compared with a net loss of $8.5 million, or a loss of $0.22 per diluted share, on net sales of $143.0 million during the same period of the prior year.

### Net Sales

Net sales - Net sales are derived from the sale of products and related freight charges, less discounts, rebates and returns.

The table below summarizes net sales by Med Tech and Med Device:

*(in thousands)*

| Net Sales | Three Months Ended Nov 30, 2021 | Nov 30, 2020 | % Change | Six Months Ended Nov 30, 2021 | Nov 30, 2020 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Med Tech | $18,886 | $13,849 | 36.4% | $36,504 | $24,335 | 50.0% |
| Med Device | 59,394 | 58,921 | 0.8% | 118,747 | 118,651 | 0.1% |
| Total | $78,280 | $72,770 | 7.6% | $155,251 | $142,986 | 8.6% |

*(in thousands)*

| Net Sales by Global Business Unit | Three Months Ended Nov 30, 2021 | Nov 30, 2020 | % Change | Six Months Ended Nov 30, 2021 | Nov 30, 2020 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Endovascular Therapies | $39,660 | $33,900 | 17.0% | $77,718 | $63,757 | 21.9% |
| Vascular Access | 25,070 | 23,930 | 4.8% | 50,026 | 52,035 | (3.9)% |
| Oncology | 13,550 | 14,940 | (9.3)% | 27,507 | 27,194 | 1.2% |
| Total | $78,280 | $72,770 | 7.6% | $155,251 | $142,986 | 8.6% |
| Net Sales by Geography |  |  |  |  |  |  |
| United States | $65,350 | $60,684 | 7.7% | $129,814 | $114,792 | 13.1% |
| International | 12,930 | 12,086 | 7.0% | 25,437 | 28,194 | (9.8)% |
| Total | $78,280 | $72,770 | 7.6% | $155,251 | $142,986 | 8.6% |

For the three months ended November 30, 2021, net sales increased $5.5 million to $78.3 million compared to the same period in the prior year. For the six months ended November 30, 2021, net sales increased $12.3 million to $155.3 million compared to the same period in the prior year. At November 30, 2021, the Company had a backlog of $4.0 million.

The Med Tech business net sales increased $5.0 million and $12.2 million for the three and six months ended November 30, 2021 compared to the same periods in the prior year, respectively. The change in sales for both periods was primarily driven by:

- Increased Auryon sales of $4.2 million and $9.0 million compared to the same periods in the prior year, respectively;
- Growth in the thrombectomy platform driven by the AngioVac business of $1.2 million and $1.9 million, compared to the same periods in the prior year, respectively, as the Company saw increased case volumes in AngioVac despite continued COVID-19 challenges along with the limited market launch of the AlphaVac product during the second quarter of fiscal year 2022; and
- Decreased NanoKnife sales of $0.7 million for the three months ended November 30, 2021 compared to the same period in the prior year and increased NanoKnife sales of $1.0 million for the six months ended November 30, 2021 compared to the same period in the prior year. The decrease for the three months ended November 30, 2021 was driven by decreased capital sales offset by a $0.2 million increase in disposable sales, mainly in Europe. For the six months ended November 30, 2021, NanoKnife disposable sales increased $1.0 million, driven by sales in the U.S. and Europe, with consistent capital sales.

The Med Device business net sales increased $0.5 million and $0.1 million for the three and six months ended November 30, 2021 compared to the same periods in the prior year, respectively. Excluding the large UK order in the first quarter of the prior year, net sales increased $5.3 million for the six months ended November 30, 2021. The change in sales for both periods was primarily driven by:

- Increased case volume for the three months ended November 30, 2021 compared to the same period in the prior year which resulted in increased sales of Core and BioSentry products of $0.7 million and $0.1 million, respectively. PICCs and Port sales also increased $0.9 million and $0.6 million, respectively with the increase in PICCs driven by sales in the U.S. and Latin America and the increase in Ports driven solely by sales in the U.S. These increases for the three months ended November 30, 2021 compared to the same period in the prior year were partially offset by decreased Venous, Midline, Radio Frequency Ablation, Microwave and Balloon sales of $0.7 million, $0.2 million, $0.5 million, $0.2 million and $0.1 million, respectively;
- Increased case volume for the six months ended November 30, 2021 compared to the same period in the prior year, which resulted in increased sales of Core and BioSentry products of $2.9 million and $0.4 million, respectively. Port sales also increased $1.9 million, driven primarily by sales in the U.S. These increases for the six months ended November 30, 2021 compared to the same period in the prior year were partially offset by decreased Venous, Midline, PICCs, Dialysis, Radio Frequency Ablation and Microwave sales of $0.1 million, $2.0 million, $1.6 million, $0.4 million, $0.4 million and $0.6 million, respectively;
- Midlines, PICCs and Ports increased $3.5 million, excluding the prior year order in the UK, for the six months ended November 30, 2021 compared to the prior year period; and
- The backlog of $4.0 million at November 30, 2021, which was primarily related to Med Device products.

### Gross Profit, Operating expenses, and Other income (expense)

*(in thousands)*

|  | Three Months Ended Nov 30, 2021 | Nov 30, 2020 | % Change | Six Months Ended Nov 30, 2021 | Nov 30, 2020 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Gross profit | $40,555 | $40,174 | 0.9% | $80,694 | $75,938 | 6.3% |
| Gross profit % of sales | 51.8% | 55.2% |  | 52.0% | 53.1% |  |
| Research and development | $8,199 | $9,712 | (15.6)% | $15,593 | $18,721 | (16.7)% |
| % of sales | 10.5% | 13.3% |  | 10.0% | 13.1% |  |
| Selling and marketing | $23,606 | $20,174 | 17.0% | $48,052 | $37,879 | 26.9% |
| % of sales | 30.2% | 27.7% |  | 31.0% | 26.5% |  |
| General and administrative | $9,678 | $9,219 | 5.0% | $18,621 | $17,776 | 4.8% |
| % of sales | 12.4% | 12.7% |  | 12.0% | 12.4% |  |

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead, exclusive of intangible amortization.

Gross profit increased by $0.4 million for the three months ended November 30, 2021 compared to the same period in the prior year. The change is primarily attributable to the following:

- Sales volume positively impacted gross profit by $3.3 million;
- Price and mix negatively impacted gross profit by $0.4 million as a result of increased sales of Vascular Access products and decreased sales of NanoKnife capital. This negative impact was partially offset by increased sales of Auryon and AngioVac products;
- Labor shortages, inflationary costs on raw materials and production volume negatively impacted gross profit by $1.7 million; and
- Start-up costs related to Auryon and AlphaVac of $0.8 million, including depreciation on Auryon placement units of $0.4 million, negatively impacted gross profit.

Gross profit increased by $4.8 million for the six months ended November 30, 2021 compared to the same period in the prior year. The change is primarily attributable to the following:

- Sales volume positively impacted gross profit by $6.9 million;
- Price and mix positively impacted gross profit by $1.3 million as a result of increased sales of Auryon and AngioVac products. This positive impact was partially offset by increased sales of Vascular Access products;
- Start-up costs related to Auryon and AlphaVac of $1.7 million, including depreciation on Auryon placement units of $0.6 million, negatively impacted gross profit; and
- Labor shortages, freight and inflationary costs on raw materials, negatively impacted gross profit by $1.7 million year over year.

Research and development expense - Research and development (“R&D”) expense includes internal and external costs to develop new products, enhance existing products, validate new and enhanced products, and manage clinical, regulatory and medical affairs.

R&D expense decreased $1.5 million and $3.1 million for the three and six months ended November 30, 2021 compared to the same period in the prior year, respectively. The change from each period is primarily attributable to:

- The timing of certain projects, which reduced R&D project expense by $0.7 million and $2.1 million for the three and six months ended November 30, 2021 compared to the same periods in the prior year, respectively; and
- Open R&D positions, which resulted in decreased compensation and benefits expense of $0.7 and $1.1 million for the three and six months ended November 30, 2021 compared to the same periods in the prior year, respectively.

Sales and marketing expense - Sales and marketing (“S&M”) expense consists primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities.

S&M expense increased $3.4 million and $10.2 million for the three and six months ended November 30, 2021 compared to the same period in the prior year, respectively. The change from each period is primarily attributable to:

- Additional headcount from the build-out of the Auryon sales and marketing teams, which increased compensation and benefits expense by $2.5 million and $6.8 million for the three and six months ended November 30, 2021 compared to the same periods in the prior year, respectively; and
- Increased travel, meeting and tradeshow expenses of $1.0 million and $3.2 million for the three and six months ended November 30, 2021 compared to the same period in the prior year, respectively, as some COVID-19 restrictions were lifted.

General and administrative expense - General and administrative (“G&A”) expense includes executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities.

G&A expense increased $0.5 million and $0.8 million for the three and six months ended November 30, 2021 compared to the same period in the prior year, respectively. The change from each period is primarily attributable to:

- Additional headcount, which increased compensation and benefits expense by $0.5 million and $1.3 million for the three and six months ended November 30, 2021 compared to the same period in the prior year, respectively; and
- Legal expense decreased $1.4 million offset by other outside consultant spend of $0.8 million for the six months ended November 30, 2021 compared to the same period in the prior year.

*(in thousands)*

|  | Three Months Ended Nov 30, 2021 | Nov 30, 2020 | $ Change | Six Months Ended Nov 30, 2021 | Nov 30, 2020 | $ Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Amortization of intangibles | $4,889 | $4,593 | $296 | $9,710 | $9,546 | $164 |
| Change in fair value of contingent consideration | $609 | $184 | $425 | $804 | $(473) | $1,277 |
| Acquisition, restructuring and other items, net | $2,253 | $1,128 | $1,125 | $4,693 | $2,447 | $2,246 |
| Other income (expense), net | $(184) | $(337) | $153 | $(692) | $(28) | $(664) |

Amortization of intangibles - Represents the amount of amortization expense that was taken on intangibles assets held by the Company.

- Amortization expense increased $0.3 million and $0.2 million, respectively, for the three and six months ended November 30, 2021 compared to the prior year periods. The increase is due to amortization relating to the Camaro intangible asset addition of $3.9 million in the first quarter of fiscal year 2022, partially offset by assets that became fully amortized in fiscal year 2021.

Change in fair value of contingent consideration - Represents changes in contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration.

- The change in the fair value for the three and six months ended November 30, 2021 is related to the Eximo contingent consideration.

Acquisition, restructuring and other items, net - Represents costs associated with mergers and acquisitions, restructuring expenses, legal costs that are related to litigation that is not in the ordinary course of business, legal settlements and other one-time items.

Acquisition, restructuring and other items, net, increased by $1.1 million and $2.2 million for the three and six months ended November 30, 2021, respectively, compared to the same period in the prior year. The change from each period is primarily attributable to:

- Legal expense, related to litigation that is outside of the normal course of business, which increased $0.9 million and $2.2 million, respectively, for the three and six months ended November 30, 2021 compared to the same period in the prior year, respectively.

Other income (expense), net - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs.

- The change in other expense of $0.2 million and $0.7 million for the three and six months ended November 30, 2021 compared to the same period in the prior year, respectively, is primarily due to unrealized foreign currency fluctuations of $0.1 million and $0.8 million, respectively.

### Income Tax Benefit

*(in thousands)*

|  | Three Months Ended Nov 30, 2021 | Nov 30, 2020 | Six Months Ended Nov 30, 2021 | Nov 30, 2020 |
| --- | ---: | ---: | ---: | ---: |
| Income tax benefit | $(0.5) | $(0.9) | $(2.1) | $(1.5) |
| Effective tax rate including discrete items | 5.8% | 17.5% | 12.3% | 14.5% |

Our effective tax rate including discrete items for the three-month periods ended November 30, 2021 and 2020 was 5.8% and 17.5%, respectively. Our effective tax rate including discrete items for the six-month periods ended November 30, 2021 and 2020 was 12.3% and 14.5%, respectively. In fiscal year 2022, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share-based compensation).

### Liquidity and Capital Resources

We regularly review our liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 global pandemic. We believe that our current cash on hand and availability under our Revolving Facility provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. We are closely monitoring receivables and payables.

Our cash and cash equivalents totaled $34.3 million as of November 30, 2021, compared with $48.2 million as of May 31, 2021. As of November 30, 2021 and May 31, 2021, total debt outstanding related to the Revolving Facility was $25.0 million and $20.0 million, respectively. The fair value of contingent consideration liability as of November 30, 2021 and May 31, 2021, was $16.5 million and $15.7 million, respectively.

The table below summarizes our cash flows:

*(in thousands)*

| Cash provided by (used in): | Six Months Ended Nov 30, 2021 | Nov 30, 2020 |
| --- | ---: | ---: |
| Operating activities | $(6,963) | $6,023 |
| Investing activities | (12,941) | (3,185) |
| Financing activities | 6,388 | 481 |
| Effect of exchange rate changes on cash and cash equivalents | (354) | 271 |
| Net change in cash and cash equivalents | $(13,870) | $3,590 |

Cash flows consisted of the following:

#### Cash provided by (used in) operating activities

Six months ended November 30, 2021 and 2020:

- Net loss of $15.3 million and $8.5 million for the period ended November 30, 2021 and 2020, respectively, plus the non-cash items, primarily driven by depreciation and amortization and stock based compensation, along with the

changes in working capital below, contributed to cash used in operations of $7.0 million and cash provided by operations of $6.0 million, respectively, for these periods.

- For the period ended November 30, 2021, working capital was negatively impacted by decreased accounts payable, accrued liabilities and other liabilities of $4.5 million, mainly driven by the payment of annual incentive compensation in the first quarter along with increased accounts receivable of $2.9 million.
- For the period ended November 30, 2020, working capital was negatively impacted by increased accounts receivable of $2.3 million and decreased accounts payable, accrued liabilities and other liabilities of $3.8 million. Inventory had a favorable impact on working capital of $10.5 million.

#### Cash used in investing activities

Six months ended November 30, 2021 and 2020:

- $2.2 million and $3.2 million, respectively, of cash was used for fixed asset additions;
- $7.2 million of cash was used for Auryon placement and evaluation unit additions in fiscal year 2022; and
- $3.6 million of cash was used for the QX Medical asset acquisition in the first quarter of fiscal year 2022.

#### Cash provided by financing activities

Six months ended November 30, 2021 and 2020:

- $5.0 million draw on the revolver in the first quarter of fiscal year 2022 for the QX Medical asset acquisition; and
- $1.4 million and $0.5 million, respectively, of proceeds from stock option and ESPP activity.

The Credit Agreement provides for a $125.0 million secured Revolving Facility, which includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. One financial covenant requires us to maintain a fixed charge coverage ratio of not less than 1.25 to 1.00. The other financial covenant requires us to maintain a total leverage ratio of not greater than 3.00 to 1.00. The total leverage ratio is based upon our trailing twelve months total adjusted EBITDA (as defined in the Credit Agreement). The amount that we can borrow under our Credit Agreement is directly based on our leverage ratio. The interest rate on the Revolving Facility at November 30, 2021 was 1.34%. The Company was in compliance with the Credit Agreement covenants as of November 30, 2021.

In the first quarter of fiscal year 2022, the Company made a $5.0 million draw on the Revolving Facility in conjunction with the QX Medical asset acquisition. In December 2020 and March 2021, payments of $10.0 million each were made on the Revolving Facility. We believe that our current cash balance, together with cash generated from operations and access to our Revolving Facility, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make acquisitions of other businesses or technologies in the future for cash, we may require external financing.

### New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note 17 to our consolidated financial statements in this Quarterly Report on Form 10-Q.

## Market risk

As filed, 2,992 characters.

### Foreign Currency Exchange Rate Risk

We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our credit facility and investments that could impact our results of operations and financial position.

We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British pound and Canadian dollar. For the six months ended November 30, 2021, approximately 7% of our sales were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other (Expenses) Income. Significant non-functional balances include accounts receivable due from a sub-section of our international customers.

### Interest Rate Risk

We have a Credit Agreement which provides for a $125.0 million Revolving Facility. Interest on the facility will be based, at the Company’s option, on either a base rate of LIBOR or alternate base rate, plus an applicable margin tied to the Company’s total leverage ratio and having ranges between 0.25% and 0.75% for base rate loans and between 1.25% and 1.75% for LIBOR loans. In the event of default, the interest rate may be increased by 2.0%. As of November 30, 2021 there was $25.0 million outstanding on the Revolving Facility. The interest rate on the Revolving Facility at November 30, 2021 was 1.34%.

### Concentration of Credit Risk

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, our credit facility and trade accounts receivable.

The Company maintains cash and cash equivalents at various institutions and performs periodic evaluations of the relative credit standings of these financial institutions to ensure their credit worthiness. In addition, the Credit Agreement is structured across five above investment grade banks. The Company has the ability to draw equally amongst the five banks which limits the concentration of credit risk of one institution.

Concentration of credit risk with respect to trade accounts receivable is limited due to the large number of customers that purchase products from the Company. No single customer represents more than 10% of total sales. The Company monitors the creditworthiness of its customers. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers. Although the Company does not currently foresee a significant credit risk associated with the outstanding accounts receivable, repayment is dependent upon the financial stability of our customers.

## Controls and procedures

As filed, 1,567 characters.

### Evaluation of disclosure controls and procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting for the fiscal quarter ended November 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

### PART II: OTHER INFORMATION

See Note 14 "Commitments and Contingencies" set forth in the notes to our consolidated financial statements included in Part I, Item I of this Quarterly Report on Form 10-Q.

## Risk factors

As filed, 684 characters.

In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2021 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.

Filed Jan 7, 2022.
Source: SEC EDGAR, the filing index for accession 0001275187-22-000005. Last ingested by Listed: Nov 4, 2026, 20:24 ET. No prices; not investment advice.
